RT Journal Article
SR Electronic
T1 Genome-wide Analysis of Copy Number Variation in Latin American Parkinson’s Disease Patients
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.29.20100859
DO 10.1101/2020.05.29.20100859
A1 Elif Irem Sarihan
A1 Eduardo Pérez-Palma
A1 Lisa-Marie Niestroj
A1 Douglas Loesch
A1 Miguel Inca-Martinez
A1 Andrea R. V. R. Horimoto
A1 Mario Cornejo-Olivas
A1 Luis Torres
A1 Pilar Mazzetti
A1 Carlos Cosentino
A1 Elison Sarapura-Castro
A1 Andrea Rivera-Valdivia
A1 Elena Dieguez
A1 Victor Raggio
A1 Andres Lescano
A1 Vitor Tumas
A1 Vanderci Borges
A1 Henrique B. Ferraz
A1 Carlos R. Rieder
A1 Artur Schumacher-Schuh
A1 Bruno L. Santos-Lobato
A1 Carlos Velez-Pardo
A1 Marlene Jimenez-Del-Rio
A1 Francisco Lopera
A1 Sonia Moreno
A1 Pedro Chana-Cuevas
A1 William Fernandez
A1 Gonzalo Arboleda
A1 Humberto Arboleda
A1 Carlos E. Arboleda-Bustos
A1 Dora Yearout
A1 Cyrus P. Zabetian
A1 Timothy A. Thornton
A1 Timothy D. O’Connor
A1 Dennis Lal
A1 Ignacio F. Mata
A1 on behalf of the Latin American Research Consortium on the Genetics of Parkinson’s Disease (LARGE-PD)
YR 2020
UL http://medrxiv.org/content/early/2020/06/02/2020.05.29.20100859.abstract
AB Background Parkinson’s disease is the second most common neurodegenerative disorder and affects people from all ethnic backgrounds, yet little is known about the genetics of Parkinson’s disease in non-European populations. In addition, the overall identification of copy number variants at a genome-wide level has been understudied in Parkinson’s disease patients.Objectives To understand the genome-wide burden of copy number variants in Latinos and its association with Parkinson’s disease.Methods We used genome-wide genotyping data from 747 Parkinson’s disease patients and 632 ancestry matched controls from the Latin American Research Consortium on the Genetics of Parkinson’s disease.Results Genome-wide copy number burden analysis showed no difference between patients vs. controls, whereas patients were significantly enriched for copy number variants overlapping known Parkinson’s disease genes compared to controls (Odds Ratio: 3.97 [1.69 - 10.5], P = 0.018). PARK2 showed the strongest copy number burden, with 20 copy number variant carriers. These patients presented an earlier age of disease onset compared to patients with other copy number variants (median age at onset: 31 years vs. 57 years, P = 7.46 x 10-7).Conclusions We found that Parkinson’s disease patients are significantly enriched with copy number variants affecting known Parkinson’s disease genes. We also identified that out of 250 patients with early-onset disease, 5.6% carried a copy number variant on PARK2 in our cohort. Our study is the first to analyze genome-wide copy number variants association in Latino Parkinson’s disease patients and provides insights about this complex disease in this understudied population.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was funded by a Stanley Fahn Junior Faculty Award from the Parkinson's Foundation and supported by a research grant from the American Parkinson's Disease Association, with resources and the use of facilities at the Veterans Affairs Puget Sound Health Care System.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by VA Puget Sound IRB, with the project name "LARGE-PD: Latin American Research Consortium of the Genetics of Parkinson's Disease", RDIS number: 0010, MIRB number: 00087. Currently, the study is under Cleveland Clinic IRB: 19-340.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll relevant data and methods are reported in the article and in the Supplement. https://github.com/elifirem/LargePD_CNV